Overview of the pipeline analysis report on car T-cell therapy for multiple myeloma
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma. Our analysts predict that the increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area.
Technavio’s pipeline analysis report on car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.
Key companies
This pipeline analysis report has identified thirteen companies that are actively involved in the development of car T-cell therapy for multiple myeloma. This report has segregated the players into Tier 1, Tier 2, and Tier 3 companies based on their revenue,. One of the Tier 1 companies Juno Therapeutics, is a major player in the biotechnology industry and has registered a revenue of more than USD 79 million in 2016.
The Tier 1 companies covered in the report are –
- Juno Therapeutics
- Kite Pharma
- Novartis
- Collectis
Therapeutic assessment of the car T-cell therapy for multiple myeloma by therapy
- Monotherapy
- Combination therapy
Monotherapy is the utilization of a single drug to treat a disease. Our analysts have identified that all the car T-cell therapy drugs that are currently in the pipeline are being developed as monotherapy agents and most of these drugs are in the Phase I and IND stage.
Segmentation of pipeline molecules in car T-cell therapy for multiple myeloma by indication
- Multiple myeloma
- Refractory or relapsed multiple myeloma
This pipeline analysis report has estimated that the multiple myeloma segment accounts for the major shares of the current pipeline and bluebird bio (bb2121), Nanjing Legend Biotech (LCAR-B38M), and Autolus (AUTO2) are few of the companies focusing on developing drugs for refractory or relapsed multiple myeloma.
Key questions answered in the report include
- What are the different stages of the pipeline molecules in investigation?
- What are the molecules in the various development stages in the car T-cell therapy for multiple myeloma?
- Who are the key companies currently involved in the development of gene therapy drugs for car T-cell therapy for multiple myeloma?
- What are the molecules discontinued from the car T-cell therapy for multiple myeloma?
- What are the major regulatory authorities approving drugs in various regions?
Technavio also offers customization on reports based on specific client requirement.